Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice

被引：43

作者：

Liu, Zeyu ^{[1
,3
]}

Guo, Zhongmin ^{[2
]}

Wang, Guoling ^{[3
]}

Zhang, Dingmei ^{[1
]}

He, Hongxuan ^{[4
]}

Li, Guowei ^{[1
]}

Liu, Yuge ^{[1
]}

Higgins, Denise ^{[5
]}

Walsh, Aoiffe ^{[5
]}

Shanahan-Prendergast, Leo ^{[5
]}

Lu, Jiahai ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Sch Publ Hlth, State Minist Educ, Key Lab Trop Dis Control Res, Guangzhou 510080, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Expt Anim, Guangzhou 510080, Guangdong, Peoples R China

[3] Haizhu Ctr Dis Control & Prevent, Guangzhou 510288, Guangdong, Peoples R China

[4] Chinese Acad Sci, Natl Res Ctr Wildlife Borne Dis, Inst Zool, Beijing 100080, Peoples R China

[5] Canopus BioPharma, Los Angeles, CA 91604 USA

来源：

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2009年 / 38卷 / 03期

关键词：

Influenza; Statin; Caffeine; Oseltamivir; Ribavirin; AVIAN INFLUENZA-VIRUSES; MURINE MODEL; CAFFEINE; STATINS; RIBAVIRIN; ADJUVANT; PHARMACOLOGY; RESISTANCE; VIRAZOLE; VACCINE;

D O I：

10.1016/j.ejps.2009.07.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The development of novel antiviral drugs is necessary for the prevention and treatment of a potential avian influenza pandemic. The aim of this study was to evaluate the efficacy and safety of a novel statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in a murine model. In H5N1-, H3N2- and H1N1-infected BALB/c mice. 50 mu g statin/200 mu g caffeine effectively ameliorated lung damage and inhibited viral replication and was at least as effective as oseltamivir and ribavirin. The statin/caffeine combination also appeared to be more effective when administered preventatively rather than as treatment. These findings provide justification for further research into this novel antiviral formulation. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：215 / 223

页数：9

共 45 条

[1] An overview of the epidemiology of avian influenza [J].

Alexander, Dennis J. .

VACCINE, 2007, 25 (30) :5637-5644

[2]

[Anonymous], CUM NUMB CONF HUM CA

[3] The safety of statins in clinical practice [J].

Armitage, Jane .

LANCET, 2007, 370 (9601) :1781-1790

[4] CLINICAL-PHARMACOLOGY OF CAFFEINE [J].

BENOWITZ, NL .

ANNUAL REVIEW OF MEDICINE, 1990, 41 :277-288

[5] RIBAVIRIN SMALL-PARTICLE-AEROSOL TREATMENT OF INFLUENZA-B VIRUS-INFECTION [J].

BERNSTEIN, DI ;

REUMAN, PD ;

SHERWOOD, JR ;

YOUNG, EC ;

SCHIFF, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :761-764

[6] Coffee and cardiovascular disease:: In vitro, cellular, animal, and human studies [J].

Bonita, Jennifer Stella ;

Mandarano, Michael ;

Shuta, Donna ;

Vinson, Joe .

PHARMACOLOGICAL RESEARCH, 2007, 55 (03) :187-198

[7] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].

Bresson, Jean-Louis ;

Perronne, Christian ;

Launay, Odile ;

Gerdil, Catherine ;

Saville, Melanie ;

Wood, John ;

Hoeschler, Katja ;

Zambon, Maria C. .

LANCET, 2006, 367 (9523) :1657-1664

[8] Caffeine analogs: biomedical impact [J].

Daly, J. W. .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (16) :2153-2169

[9] Brief report - Oseltamivir resistance during treatment of influenza A (H5N1) infection [J].

de Jong, MD ;

Thanh, TT ;

Khanh, TH ;

Hien, VM ;

Smith, GJD ;

Chau, NV ;

Cam, BV ;

Qui, PT ;

Ha, DQ ;

Guan, Y ;

Peiris, JSM ;

Hien, TT ;

Farrar, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2667-2672

[10] Use of neuraminidase inhibitors to combat pandemic influenza [J].

Democratis, Jane ;

Pareek, Manish ;

Stephenson, Iain .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (05) :911-915

← 1 2 3 4 5 →